Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 471 to 480 of 842 total matches.
Corneal Surgery for Correction of Refractive Errors
The Medical Letter on Drugs and Therapeutics • Dec 17, 1999 (Issue 1068)
reading glasses.
Adverse Effects − The risk of a vision-threatening infection after LASIK is 1 to 5 per ...
All refractive corneal surgery reshapes the cornea to redirect light rays so that they focus on the retine....
Alefacept (Amevive) For Treatment of Psoriasis
The Medical Letter on Drugs and Therapeutics • Apr 14, 2003 (Issue 1154)
and inflammation. An increase in opportunistic
infections has not been reported. Since the drug decreases ...
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.
Efalizumab (Raptiva) for Treatment of Psoriasis
The Medical Letter on Drugs and Therapeutics • Dec 08, 2003 (Issue 1171)
inhibitors, some serious acute infections and reactivation of latent chronic infections have been reported ...
Efalizumab (Raptiva - Genentech/XOMA), a humanized monoclonal antibody that inhibits T-cell activation, has been approved by the FDA for treatment of adults with moderate to severe chronic plaque psoriasis.
Ophthalmic Azithromycin (AzaSite)
The Medical Letter on Drugs and Therapeutics • Feb 11, 2008 (Issue 1279)
appear to be effective for most cases of this generally self-limited
infection.
Sulfacetamide is widely ...
The FDA has approved azithromycin 1% ophthalmic solution (AzaSite - Inspire) for treatment of bacterial conjunctivitis in patients > 1 year old. It is formulated, according to the manufacturer, in a controlled-release delivery system that keeps the drug in the eye for several hours.
Botox for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Apr 15, 2013 (Issue 1414)
of
Botox for treatment of overactive bladder, the most
common side effect was urinary tract infection ...
The FDA has recently approved intradetrusor injection
of onabotulinumtoxinA (Botox – Allergan) for treatment
of overactive bladder in patients who cannot tolerate or
have an inadequate response to anticholinergic therapy.
Botox is also approved by the FDA for use in
detrusor overactivity associated with a neurologic condition
such as multiple sclerosis or spinal cord injury,
and for chronic migraine, upper limb spasticity, axillary
hyperhidrosis, cervical dystonia, blepharospasm, strabismus,
and cosmetic reduction of wrinkles.
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jun 10, 2013 (Issue 1418)
, fatigue, arthralgia, depression, C 300 mg IV every 52,449.00
(Biogen Idec) infections, hypersensitivity ...
The FDA has approved dimethyl fumarate (Tecfidera –
Biogen Idec), formerly called BG-12, for treatment of
relapsing forms of multiple sclerosis (MS). It is the
third oral drug to be approved in recent years for this
indication.
Vedolizumab (Entyvio) for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
may have an increased risk of infection. Increased
transaminases and bilirubin levels have been reported.
Progressive ...
The FDA has approved vedolizumab (Entyvio - Takeda),
an intravenous integrin receptor antagonist, for treatment
of moderate to severe ulcerative colitis or Crohn's
disease in adults who have not responded to, lost
response to, or cannot tolerate standard treatment.
Natalizumab (Tysabri), another integrin receptor antagonist,
has been available for several years for treatment
of Crohn's disease and multiple sclerosis.
Ciprofloxacin/Fluocinolone (Otovel) for Otitis Media with Tympanostomy Tubes
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
, primarily due to bacterial
infection, is the most common complication of
tympanostomy tubes. Topical ...
The FDA has approved Otovel (Arbor), a combination
of the fluoroquinolone antibiotic ciprofloxacin 0.3% and
the corticosteroid fluocinolone acetonide 0.025%, for
otic treatment of acute otitis media with tympanostomy
tubes (AOMT) in children ≥6 months old. It is the
second fluoroquinolone/corticosteroid combination
to be approved for this indication; ciprofloxacin 0.3%/dexamethasone 0.1% (Ciprodex) has been available
for many years. In December 2015, a suspension
of ciprofloxacin 6% (Otiprio) was approved for otic
treatment of bilateral otitis media with effusion in
children...
Kyleena - Another Hormonal IUD
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017 (Issue 1515)
0.4 13.5 mg 714.70
LNG = levonorgestrel; STIs = sexually transmitted infections
1. FDA-approved ...
The FDA has approved Kyleena (Bayer), an intrauterine
device (IUD) that releases the synthetic progestin
levonorgestrel, for prevention of pregnancy. It is the
fourth levonorgestrel-releasing IUD to be approved in
the US. Like Mirena, which has been available since
2000, Kyleena is approved for up to 5 years of use.
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
tract
infection, sinusitis, defecation
urgency, fecal incontinence, dyspepsia,
viral gastroenteritis ...
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation